英文文献汇报.pptxVIP

;;1. Introduction; DNA vaccines have been shown to induce strong humoral and cellular responses to malarial antigens in immunized. However, clinical trials of these candidate vaccines when used alone or in repeated homologous boosting regimens have been disappointing, with short lived low levels of induced specific T-cells responses. Sequential immunization with different plasmids/vectors known as heterologous prime-boosting appears to be a better approach and has been shown to induce enhanced and persistent levels of antibody and cell mediated immune responses against malaria. In heterologous prime-boosting strategy the priming was done with DNA followed by the booster immunization with a recombinant protein, a recombinant viral vaccine, or exposure to the live organism. In the present study we have evaluated the immunogenicity of a DNA vaccine encoding MSP-1 42 of P. vivax using prime-boosting strategy in BALB/c mice. We have also compared the immunogenicity of PvMSP-1 42 recombinant protein in BALB/c mice.;2. Materials and methods;3. Results3.1. Construction of a P. vivax merozoite surface protein-1 42 -pcDNA 3.1 plasmid DNA vaccine and its in vitro expression in COS1 cells;3.2. Antibody responses in immune mice against P. vivax merozoite surface protein-1 42 -pcDNA3.1 DNA vaccine construct and recombinant PvMSP-1 42 protein;3.3. Measurement of P. vivax merozoite surface protein-1 42 specific IgG isotypes in immune mice sera;3.4. In vitro T cell responses against P. vivax merozoite surface protein-1 42;3.5. In vitro cytokines production against P. vivax merozoite surface protein-1 42;4. Discussions; The importance of heterologous prime-boost strategy in malaria infection has been demonstrated by a number of studies. In the present study, priming with P. vivax MSP-1 42 plasmid DNA and boosting with recombinant PvMSP-142 protein exhibited a significant increase in the antibody responses in DNA/Protein group compared to DNA/DNA group as it was evident